Bis-heteroaryl alkanes as therapeutic agents
View Patent ↗This invention provides compounds which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases in mammals mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease.
1. A compound of Formula (I):
wherein
R 1 and R 2 are independently selected from the group consisting of
R 3 is
(a) hydrogen;
(b) alkyl;
(c) alkenyl; or
(d) alkynyl;
R 4 in combination with R 5 is: 5-carboxy -2-furyl; 5-hydroxymethylfuran-2-yl; or 5-methoxycarbonylmethoxymethyl-2-furyl;
R 6 , R 6 ′, R 7 , R 7 ′, R 8 , and R 8 ′ are independently selected from the group consisting of
(a) hydrogen;
(b) aryl;
(c) heteroaryl;
(d) heterocyclyl;
(e) cycloalkyl;
(f) halogen; and
(g) -alkylene-Y-aryl; -alkenylene-Y-aryl; -alkynylene-Y-aryl; -alkylene-Y-heteroaryl; -alkenylene-Y-heteroaryl; -alkynlene-Y-heteroaryl; -alkylene-Y-cycloalkyl -alkenylene-Y-cycloalkyl; -alkynlene-Y-cycloalkyl; -alkylene-Y-heterocyclyl; -alkenylene-Y-heterocyclyl; -alkynlene-Y-heterocyclyl; —Y-alkyl; —Y-aryl; —Y-alkylene-aryl; —Y-alkylene-NR 11 R 12 ; —Y—O—Si-(alkyl) 3 ; and —Y—O—Si-(alkylene-aryl) 3 ;
wherein
Y is —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O 2 )—, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHS(O 2 )—, —S(O 2 )N(H)—, —C(O)—O—, —NHS(O 2 )NH—, or —O—CO—; and
R 11 and R 12 are independently selected from the group consisting of: hydrogen, aryl, alkyl, and alkylene-aryl; or
R 11 and R 12 are taken together to form a ring having the formula —(CH 2 ) q -Q-(CH 2 ) r — bonded to the nitrogen atom to which R 11 and R 12 are attached, wherein q and r are, independently, 1, 2, 3, or 4; Q is —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —SO 2 —, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHSO 2 —, —SO 2 N(H)—, —(O)CO—, —NHSO 2 NH—, —OC(O)—, —N(R 13 )—, —N(C(O)R 13 )—, —N(C(O)NHR 13 )—, —N(SO 2 NHR 13 )—, —N(SO 2 R 13 )—, or —N(C(O)OR 13 )—; or
R 11 and R 12 are taken together, with the nitrogen atom to which they are attached, to form a heterocyclyl or heteroaryl ring;
R 9 , R 10 , and R 13 are independently selected from the group consisting of hydrogen, aryl, alkyl, and alkylene-aryl;
A 1 and A 2 are N—R 14 , where R 14 is
(a) alkyl; or
(b) -alkylene-aryl
R 17 and R 18 are independently selected from the group consisting of hydrogen, alkyl, and halogen;
Ar 1 and Ar 2 are phenyl;
or a pharmaceutically acceptable salt, solvate or prodrug thereof.
2. The compound of Formula (I) of claim 1 , wherein R 1 and R 2 are independently selected from the group consisting of: 1-methylindol-3-yl; 4-chloro-1-methylindol-3-yl; 4-chloro-1-ethylindol-3-yl; 4-chloro-1-butylindol-3-yl; 4-chloro-1-benzylindol-3-yl; and 4-chloro-1-benzylindol-3-yl.
3. The compound of Formula (I) of claim 1 , wherein at least one of R 6 , R 6 ′, R 7 , R 7 ′, R 8 , and R 8 ′is halogen.
4. The compound of Formula (I) of claim 1 , wherein R 6 , R 6 ′, R 7 , R 7 ′, R 8 , and R 8 ′are independently selected from the group consisting of hydrogen, halogen, alkyl, and —O-alkylene-phenyl group.
5. A compound selected from the group consisting of: Bis(1-methylindol-3-yl)-(5-hydroxymethyl-2-furyl)methane, Bis(4-chloro-1-methylindol-3-yl)-(5-hydroxymethyl-2-furyl)methane, Bis(1-methylindol-3-yl)-(5-methoxycarbonylmethoxymethyl-2-furyl)methane, Bis(1-methylindol-3-yl)-(5-carboxymethoxymethyl-2-furyl)methane, and Bis(4-chloro-1-benzylindol-3-yl)-(5-hydroxymethyl-2-furyl)methane.
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of a compound of the Formula:
wherein
R 1 and R 2 are independently selected from the group consisting of
R 3 is
(a) hydrogen;
(b) alkyl;
(c) alkenyl; or
(d) alkynyl;
R 4 is heteroarylene;
wherein
R 4 is optionally substituted with a substituent of the formula
wherein
L 1 is a direct bond, alkylene, —O-alkylene-, alkylene-O—, —NH—C(O)—, —C(O)—NH—or —NH—CO—NH—;
L 2 is alkyline, alkenyline, heteroaryline, aryline, or heterocyclyline;
L 3 is —O—, —C(O)—N(R 19 )—, —C(O)—O—, —C(O)—, or —N(R 19 )—CO—N(R 20 )—;
L 4 is H, alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl, alkylene-aryl;
L 5 is hydrogen, alkyl, alkenyl, alkynyl, -alkylene-aryl, -alkylene-heteroaryl, alkylene-O-alkylene-aryl, -alkylene-S-alkylene-aryl, -alkylene-O-alkyl, -alkylene-S-alkyl, -alkylene-NH 2 , -alkylene-OH, -alkylene-SH, -alkylene-C(O)—OR 9 , -alkylene-C(O)—NR 9 R 10 , -alkylene-NR 9 R 10 , -alkylene-N(R 9 )—C(O)—R 10 , -alkylene-N(R 9 )—S(O 2 )—R 10 ; or
may be taken together to constitute a direct bond;
R 5 is
(a) hydrogen;
(b) alkyl;
(c) alkenyl;
(d) alkynyl;
(e) aryl;
(f) heteroaryl;
(g) cycloalkyl;
(h) heterocyclyl;
(i) alkylene-OH;
(j) alkylene-COOH;
(k) alkylene-NH 2 ;
(l) COOH;
(m) CONH 2 ; or
(n) NH 2 ;
R 6 , R 6 ′, R 7 , R 7 ′, R 8 , and R 8 ′ are independently selected from the group consisting of
(a) hydrogen;
(b) aryl;
(c) heteroaryl;
(d) heterocyclyl;
(e) cycloalkyl;
(f) halogen; and
(g) -alkylene-Y-aryl; -alkenylene-Y-aryl; -alkynylene-Y-aryl; -alkylene-Y-heteroaryl; -alkenylene-Y-heteroaryl; -alkynlene-Y-heteroaryl; -alkylene-Y-cycloalkyl-alkenylene-Y-cycloalkyl; -alkynlene-Y-cycloalkyl; -alkylene-Y-heterocyclyl; -alkenylene-Y-heterocyclyl; -alkynlene-Y-heterocyclyl; —Y-alkyl; —Y-aryl; —Y-alkylene-aryl; —Y-alkylene-NR 11 R 12 ; —Y—O—Si-(alkyl) 3 ; and —Y—O—Si-(alkylene-aryl) 3 ;
wherein
Y is —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —S(O 2 )—, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHS(O 2 )—, —S(O 2 )N(H)—, —C(O)—O—, —NHS(O 2 )NH—, or —O—CO—; and
R 1 and R 12 are independently selected from the group consisting of: hydrogen, aryl, alkyl, and alkylene-aryl; or
R 11 and R 12 are taken together to form a ring having the formula —(OH 2 ) q -Q-(CH 2 ) r — bonded to the nitrogen atom to which R 11 and R 12 are attached, wherein q and r are, independently, 1, 2, 3, or 4; Q is —CH 2 —, —C(O)—, —O—, —N(H)—, —S—, —S(O)—, —SO 2 —, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHSO 2 —, —SO 2 N(H)—, —(O)CO—, —NHSO 2 NH—, —OC(O)—, —N(R 13 )—, —N(C(O)R 13 )—, —N(C(O)NHR 13 )—, —N(SO 2 NHR 13 )—, —N(SO 2 R 13 )—, or —N(C(O)OR 13 )—; or
R 11 and R 12 are taken together, with the nitrogen atom to which they are attached, to form a heterocyclyl or heteroaryl ring;
R 9 , R 10 , R 13 , R 19 , and R 20 are independently selected from the group consisting of hydrogen, aryl, alkyl, and alkylene-aryl;
A 1 and A 2 are N—R 14 , where R 14 is
(a) alkyl; or
(b) -alkylene-aryl;
R 17 and R 18 are independently selected from the group consisting of hydrogen, alkyl, and halogen;
Ar 1 and Ar 2 are phenyl;
or a pharmaceutically acceptable salt, solvate or prodrug thereof.
7. The pharmaceutical composition of claim 6 , in the form of an oral dosage or parenteral dosage unit.
8. The pharmaceutical composition of claim 6 , wherein said compound is administered as a dose in a range from about 0.01 to 500 mg/kg of body weight per day.
9. The pharmaceutical composition of claim 6 , wherein said compound is administered as a dose in a range from about 0.1 to 200 mg/kg of body weight per day.
10. The pharmaceutical composition of claim 6 , wherein said compound is administered as a dose in a range from about 0.1 to 100 mg/kg of body weight per day.
11. The pharmaceutical composition of claim 6 , further comprising one or more therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, insulin, cholinesterase inhibitors, antipsychotics, antidepressants, and anticonvulsants.
12. The pharmaceutical composition of claim 6 , wherein R 1 and R 2 of the compound of Formula (I) are independently selected from the group consisting of: 1-methylindol-3-yl; 4-chloro-1-methylindol-3-yl; 4-chloro-1-ethylindol-3-yl; 4-chloro-1-butylindol-3-yl; 4-chloro-1-benzylindol-3-yl; and 4-chloro-1-benzylindol-3-yl.
13. The pharmaceutical composition of claim 6 , wherein R 4 in combination with R 5 is 5-carboxy-2-furyl; 5-hydroxymethylfuran-2-yl; or 5-methoxycarbonylmethoxymethyl-2-furyl.
14. The pharmaceutical composition of claim 6 , wherein R 6 , R 6 ′, R 7 , R 7 ′, R 8 , and R 8 ′ of the compound of Formula (I) are independently selected from the group consisting of: hydrogen, halogen, alkyl, and —O-alkylene-phenyl.
15. The pharmaceutical composition of claim 6 , wherein R 1 and R 2 are independently selected from the group consisting of: 1-methylindol-3-yl; 4-chloro-1-methylindol-3-yl; 4-chloro-1-ethylindol-3-yl; 4-chloro-1-butylindol-3-yl; 4-chloro-1-benzylindol-3-yl; and 4-chloro-1-benzylindol-3-yl; and R 4 in combination with R 5 is 5-carboxy-2-furyl; 5-hydroxymethylfuran-2-yl; or 5-methoxycarbonylmethoxymethyl-2-furyl.
16. The pharmaceutical composition of claim 6 , wherein the compound of Formula (I) is selected from the group consisting of: Bis(1-methylindol-3-yl)-(5-hydroxymethyl-2-furyl)methane, Bis(4-chloro-1-methylindol-3-yl)-(5-hydroxymethyl-2-furyl)methane, Bis(1-methylindol-3-yl)-(5-methoxycarbonylmethoxymethyl-2-furyl)methane, Bis(1-methylindol-3-yl)-(5-carboxymethoxymethyl-2-furyl)methane, and Bis(4-chloro-1-benzylindol-3-yl)-(5hydroxymethyl-2furyl)methane.